MPTC Physician Publications
Ferris M, Molitoris J, Tran PT, et al. Author correction: Identification of CT based radiomic biomarkers for progression free survival in head and neck squamous cell carcinoma, February 2025.
Tran PT, et al. Predicting dose response to prostate cancer radiotherapy: Validation of a radiation signature in the randomized phase III NRG/RTOG
0126 and SAKK 09/10 trials, February 2025.
Ferris MJ, Molirotis JK, et al. Adjuvant proton radiation following transoral robotic surgery for HPV-positive oropharyngeal squamous cell carcinoma, February 2025.
Tran PT, et al. Integrating prostate surface membrane antigen-PET into clinical practice for prostate cancer, February 2025.
Tran PT, et al. The benefit of short-term androgen deprivation therapy with radiotherapy for intermediate-risk prostate cancer, February 2025.
Molitoris J, Ferris M, Tran PT, et al. Identification of CT based radiomic biomarkers for progression free survival in head and neck squamous cell carcinoma., January 2025.
Tran PT, et al. Evaluating the prognostic impact of apparent diffusion coefficient in definitive radiotherapy for Gleason score 7 prostate cancer patients, December 2024.
Molitoris J, et al. Proton Beam Therapy for Pancreatic Tumors: A Consensus Statement from the Particle Therapy Cooperative Group Gastrointestinal Subcommittee, December 2024.
Mishra MV, et al. Consensus radiation treatment planning guidelines using (68)Ga-DOTATATE PET/CT for resected meningiomas, December 2024.
Tran PT, et al. Evaluating the prognostic impact of apparent diffusion coefficient in definitive radiotherapy for Gleason score 7 prostate cancer patients. December 2024.
Nichols E, McAvoy S, et al. Cancer outcomes and cardiopulmonary toxicities for black patients with breast cancer treated with proton therapy, December 2024.
Tran PT, et al. Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: A combined analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase 3 trials. November 2024.
Tran PT, et al. Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castrationsensitive prostate cancer. November 2024.
Rana Z, Mishra M, et al. The use of external beam radiation therapy for heterotopic ossification prophylaxis after surgical fixation of acetabular fractures: A randomized controlled trial. November 2024.
Tran PT, et al. Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: A combined analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase 3 trials, November 2024.
Rana Z, Mishra M, et al. The use of external beam radiation therapy for heterotopic ossification prophylaxis after surgical fixation of acetabular fractures: A randomized controlled trial, November 2024.
Mishra MV, et al. Weight loss, pathological changes, and inflammatory effects from a short-term ketogenic diet in overweight and obese men with untreated prostate cancer on active surveillance, November 2024.
Regine W, et al. Results of an integrated phase I/II prospective clinical trial (NEXIS) for neoadjuvant anti-PD-L1 (durvalumab) and anti-CTLA-4 (tremelimumab) with radiation for high-risk soft-tissue sarcoma of the trunk and extremities. October 2024.
Mishra MV, et al. Weight loss, pathological changes, and inflammatory effects from a short-term ketogenic diet in overweight and obese men with untreated prostate cancer on active surveillance. October 2024.
Regine W, et al. Results of an integrated phase I/II prospective clinical trial (NEXIS) for neoadjuvant anti-PD-L1 (durvalumab) and anti-CTLA-4 (tremelimumab) with radiation for high-risk soft-tissue sarcoma of the trunk and extremities., October 2024.
Tran PT, et al. Patient-specific deep learning for 3D protoacoustic image reconstruction and dose verification in proton therapy. July 2024.
Tran PT, et al. PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. July 2024.
McAvoy SA, et al. Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. July 2024.
Tran P, et al. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics, July 2024.
Mishra M, Rana Z, Molitoris J, Ferris M, et al. Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer, June 2024.
Tran P, et al. Evaluation of treatment outcomes of prostate cancer patients with lymph node metastasis treated with definitive radiotherapy: Comparative analysis of PSMA PET/CT and conventional imaging., June 2024.
Molitoris J, Ferris M, Regine W, Tran P, et al. Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer, June 2024.
Molitoris JK, Ferris M, Regine WF, et al. Clinical implementation and dosimetric evaluation of a robust proton lattice planning strategy using primary and robust complementary beams., June 2024.
Mishra MV, et al. Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients, May 2024.
Nichols EM, Mishra MV, et al. Validation of patient-reported outcomes in patients with nonmetastatic breast cancer receiving comprehensive nodal irradiation in the RadComp trial, May 2024.
Molitoris JS, Tran P, Rana Z, Mishra MV, et al. Conditional risk and predictive factors associated with late toxicity for prostate cancer patients treated with external beam radiotherapy alone on randomized trial RTOG 0126., May 2024.
Tran PT, Rana Z, et al. Prognostic significance of immune cell infiltration in muscleinvasive bladder cancer treated with definitive chemoradiation: A secondary analysis of RTOG 0524 and RTOG 0712, April 2024.
Tran PT, et al. TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy, April 2024.
Tran PT, et al. Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans, April 2024.
Tran PT, et al. Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer, April 2024.
Molitoris J, et al. SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids, March 2024.
McAvoy SA, et al. Patient education practices and preferences of radiation oncologists and interprofessional radiation therapy care teams: A mixed methods study exploring strategies for effective patient education delivery, March 2024.
Tran PT, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy, February 2024.
Tran PT, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy, February 2024.
Tran PT, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions, February 2024.
Regine WF, et al. Practice patterns of spatially fractionated radiation therapy: A clinical practice survey, February 2024.
Nichols E, McAvoy S, et al. Psychosocial factors that influence a woman’s decision to enroll in a clinical trial – implications on how to improve clinical trial enrollment among Black women, February 2024.
Tran PT, et al. The potential contribution of radiopharmaceutical therapies in managing oligometastatic disease, February 2024.
Tran PT, et al. Cardiovascular mortality and duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG/RTOG 9202, February 2024.
Molitoris JK, Ferris MJ, et al. Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy, February 2024.
Tran PT, et al. Stereotactic ablative radiation therapy in metastatic prostate cancer, February 2024.
Molitoris JK, Regine WF, Tran PT, et al. A longitudinal metagenomic comparative analysis of oral microbiome shifts in patients receiving proton radiation versus photon radiation for head and neck cancer, January 2024.
Mishra MV, et al. Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001, January 2024.
Mishra MV, et al. Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology’s RTOG 0614, December 2023.
Molitoris J, et al. Identification of CT-based non-invasive radiomic biomarkers for overall survival prediction in oral cavity squamous cell carcinoma, December 2023.
Ferris MJ, et al. Is noncoplanar plan more robust to inter-fractional variations than coplanar plan in treating bilateral HN tumors with pencil-beam scanning proton beams, November 2023.
Nichols EM, et al. Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline, November 2023.
Kwok Y, et al. NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma, October 2023.
Molitoris J, et al. Dosimetric evaluation and reproducibility of breath-hold plans in intensity modulated proton therapy: An initial clinical experience, October 2023.
Rana Z, Tran PT, et al. Identification of a predictive genomic biomarker for prostate-directed therapy in synchronous low-volume metastatic castration-sensitive prostate cancer, August 2023.
Nichols EM, et al. Clinical outcomes of intensity modulated proton therapy reirradiation for gynecologic malignancies, August 2023.
Kunaprayoon D, et al. Interpretable AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases, August 2023.
Mishra MV, et al. Body composition and mortality in men receiving prostate radiotherapy: A
pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126, February 2023.
Molitoris JK. Start combining, stop comparing, February 2023.
Tran PT, et al. Griseofulvin radiosensitizes non-small cell lung cancer cells and activates cGAS, February 2023.
Molitoris JK, et al. How many brain metastases can be treated with stereotactic radiosurgery before the radiation dose delivered to normal brain tissue rivals that associated with standard whole brain radiotherapy, January 2023.
Molitoris J, Regine WF, et al. WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer, January 2023.
Tran PT, et al. A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscleinvasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study, January 2023.
Regine WF, Molitoris JS, et al. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience, 2023.
Tran PT, et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials, December 2022.
Tran PT, et al. Genomic classifiers in personalized prostate cancer radiotherapy approaches–a systematic review and future perspectives based on international consensus., December 2022.
Kunaprayoon D, et al. AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases using three-path three-dimensional CNN, December 2022.
Tran PT, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial, November 2022.
Tran PT, et al. Evaluating potential overuse of surveillance care in cancer survivors., November 2022.
Molitoris JK, et al. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma, November 2022.
Tran PT, et al. From idea to clinical practice: A brief history of oligometastatic disease, November 2022.
Molitoris JK, Mishra MV, Rana Z, Kwok Y, et al. Racial analysis of clinical & biochemical outcomes in prostate cancer patients treated with low-dose-rate brachytherapy, November 2022.
Tran PT, et al. Stereotactic body radiation therapy for oligometastasis: GUst do it?, November 2022.
Tran P, et al. The 5-hydroxymethylcytosine landscape of prostate cancer, October 2022.
Tran P, et al. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy, October 2022.
Molitoris JK, et al. Evaluation of intrafraction couch shifts for proton treatment delivery in head-and-neck cancer patients: Toward optimal imaging frequency, October 2022.
Tran PT, et al. Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasisdirected treatment in oligometastatic genitourinary cancers, October 2022.
Nichols E, et al. Consensus quality measures and dose constraints for breast cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology (ASTRO) Expert Panel, September 2022.
Tran PT, et al. External beam radiotherapy with or without brachytherapy boost in men with very high-risk prostate cancer: A large multicenter international consortium analysis, September 2022.
Mishra MV, et al. Quality of life and cognitive function evaluations and interventions for patients with brain metastases in the radiation oncology clinic, September 2022.
Nichols E, et al. Proton arc therapy vs interstitial HDR brachytherapy in gynecologic cancer with parametrial/pelvic side wall extension, August 2022.
Tran PT, et al. Implementing survivorship care planning in two contrasting health systems: Lessons learned from a randomized controlled trial, August 2022.
Tran PT, et al. Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy, August 2022.
Mishra M, Rana Z, Molitoris J, Tran PT, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials, August 2022.
Molitoris JK, Merris MJ, Rana Z, Mishra MV, Kwok Y, et al. Genomic biomarkers to guide precision radiotherapy in prostate cancer, August 2022.
Mishra MV, et al. 68Ga-DOTATATE PET: The future of meningioma treatment, June 2022.
Mishra MV, et al. Exposure to radon and heavy particulate pollution and incidence of brain tumors, June 2022.
Molitoris JK, Regine WF, et al. Radiation therapy and malignant fistulae of anorectal cancers, June 2022.
Tran PT, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials, June 2022.
Mishra MV, et al. Methodological comparison of mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415, June 2022.
Mishra MV, et al. Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539, June 2022.
Molitoris JK, et al. Validation of a commercial software dose calculation for Y-90 microspheres, May 2022.
Tran, et al. Paving the road to the future of chemoradiotherapy in muscle-invasive bladder cancer: 10-year follow-up of BC2001, May 2022.
Tran PT, et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer, April 2022.
McAvoy S, Mishra M, et al. From beaming cancer to beaming parent: Paternity leave experiences in radiation oncology, April 2022.
Tran P, et al. Patient-specific deep learning model to enhance 4D-CBCT image for radiomics analysis, April 2022.
Rana ZH, et al. Burnout in radiation oncology physician workforce: The effect of mindfulness and fulfillment, April 2022.
McAvoy SA, Nichols EM, et al. Correlation of treatment time to target volume for GammaPod treatments: A simple second calculation, February 2022.
Mishra MV, Molitoris JK, et al. Administering docetaxel for metastatic hormone-sensitive prostate cancer 1-6 days compared to more than 14 days after the start of LHRH agonist is associated with better clinical outcomes due to androgen flare, February 2022.
Tran PT, et al. Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: A patient-level data analysis of 3 cohorts, January 2022.
Tran PT, et al. Simplifying survivorship care planning: A randomized controlled trial comparing 3 care plan delivery approaches, January 2022.
Tran PT, et al. The promise of metastasis-directed therapy for oligometastatic prostate cancer—Going beneath the surface with molecular imaging, January 2022.
Tran PT, et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics, January 2022.
Tran PT, et al. Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?, January 2022.
Tran PT, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation, January 2022.
Kwok Y, et al. Quality of life implications of dose-escalated external beam radiation for localized prostate cancer: Results of a prospective randomized phase 3 clinical trial, NRG/RTOG 0126, January 2022.
Tran PT, et al. Performance of a prostate-specific membrane antigen positron emission tomography/computed tomography-derived risk-stratification tool for high-risk and very high-risk prostate cancer, December 2021.
Tran PT, et al. An expert review on the combination of relugolix with definitive radiation therapy for prostate cancer, December 2021.
Ferris M, et al. ASO Visual Abstract: Impact of metastasectomy and aggressive local therapy in newly diagnosed metastatic soft tissue sarcoma: An analysis of the NCDB, December 2021.
Regine WF, et al. An international consensus on the design of prospective clinical-translational trials in spatially fractionated radiation therapy, December 2021.
Tran P, et al. BCG invokes superior STINGmediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer, November 2021.
Tran PT, et al. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: A systematic review, November 2021.
Kwok Y, et al. Variation in proton craniospinal irradiation practice patterns in the United States: A Pediatric Proton Consortium Registry (PPCR) Study, November 2021.
Nichols EM, et al. Intensity modulated proton therapy treatment planning for postmastectomy patients with metallic port tissue expanders, November 2021.
Molitoris J, et al. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma, September 2021.
Kwok Y, et al. Long-term report of a comprehensive molecular and genomic analysis in NRG Oncology/RTOG 0424: A phase II study of radiation and
temozolomide in high-risk grade II glioma, September 2021.
Mishra M, et al. 68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas, August 2021.
Nichols E, et al. Comparison of the dosimetric accuracy of proton breast treatment plans delivered with SGRT and CBCT setups, July 2021.
Ferris M, et al. ASO visual abstract: Impact of metastasectomy and aggressive local therapy in newly diagnosed metastatic soft tissue sarcoma: An analysis of the NCDB, July 2021.
McAvoyt SA, et al. Phase II trial of proton therapy versus photon IMRT for GBM: Secondary analysis comparison of progression-free survival between RANO versus clinical assessment, June 2021.
Mishra MV, Nichols E, et al. Outcomes of and treatment planning considerations for a hybrid technique delivering proton pencil-beam scanning radiation to women with metal-containing tissue expanders undergoing post-mastectomy radiation, June 2021.
Mishra MV, Rana Z, Molitoris JK, et al. High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation, May 2021.
Mishra MV, et al. Preoperative radiosurgery for resected brain metastases: the PROPS-BM multicenter cohort study, May 2021.
Mishra MV, et al. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415, April 2021.
Kwok Y, et al. Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus, April 2021.
Regine WF, Mishra MV, et al. Plan quality effects of maximum monitor unit constraints in pencil beam scanning proton therapy for central nervous system and skull base tumors., March 2021.
Molitoris JK, et al. Impact of the novel coronavirus 2019 (COVID-19) pandemic on head and neck cancer care, March 2021.
Miller RC, et al. Proton beam therapy utilization in adults with primary brain tumors in the United States. Journal of Clinical Neuroscience, May 2020.
Mohindra P, et al. Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: A phase I trial from the University of Florida and Proton Collaborative Group. International Journal of Radiation Oncology • Biology • Physics, April 2020.
DeCesaris CM, McCarroll R, Mishra MV, Regine WF, Molitoris JK, et al. Assessing outcomes of patients treated with re-irradiation utilizing proton pencil-beam scanning for primary or recurrent malignancies of the esophagus and gastroesophageal junction. Journal of Thoracic Oncology, March 2020.
Siddiqui O, Pollock A, Samanta S, Kaiser A, Molitoris JK. Proton beam therapy in liver malignancies. Current Oncology Reports, Volume 22, Issue 3, Article 30, March 2020.
Regine WF, Vyfhuis M, Snider J, et al. Excellent Pathologic Response and Atypical Clinical Course of High-Grade Extremity Sarcoma to Neoadjuvant Pencil Beam Scanning Proton Therapy. Cureus, Volume 9, Issue 9, e1687, September 2019.
DeCesaris C, Rice S, Bentzen S, Jatczak J, Mishra M, Nichols E. Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. International Journal of Radiation Oncology • Biology • Physics, Volume 104, Issue 5, Pages 1084-1090, August 2019.
Mohindra P, et al. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Practical Radiation Oncology, Volume 9, Issue 4, Pages 280-288, July-August 2019.
Kaiser A, Molitoris JK Proton beam therapy for liver cancers. Journal of Gastrointestinal Oncology, July 2019.
Nichols E, Bentzen S, Suntharalingam M, Regine WF, et al. The Downstream Effect of a Proton Treatment Center on an Academic Medical Center. International Journal of Radiation Oncology • Biology • Physics, July 2019.
Mohindra P, Regine WF, Miller RC, et al. The Insurance Approval Process for Proton Beam Therapy Must Change: Prior Authorization Is Crippling Access to Appropriate Healthcare. International Journal of Radiation Oncology • Biology • Physics, Volume 104, Issue 4, Pages 737-739, July 2019.
Kaiser A, Haskins C, Siddiqui MM, Hussain A, D’Adamo C. The evolving role of diet in prostate cancer risk and progression. Current Opinion in Oncology, Volume 31, Issue 3, Pages 222-229, May 2019.
Kwok Y, et al. Patterns of proton therapy use in pediatric cancer management in 2016: an international survey. Radiotherapy and Oncology, Volume 132, Pages 155-161, March 2019.
Kaiser A, Eley JG, Onyeuku NE, Rice SR, Wright CC, McGovern NE, Sank M, Zhu M, Vujaskovic Z, II CB, Hussain A. Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies. Journal of Visualized Experiments, February 2019.
https://www.jove.com/video/58372/proton-therapy-delivery-its-clinical-application-select-solid-tumor
Kaiser A, Berman B, Regine WF, et al. Integrative Wellness for Patients Receiving Proton Therapy: A Patient-Centered Collaboration. Journal of Alternative and Complementary Medicine, Volume 24, Issue 9-10, Pages 1012-1013, September-October 2018.
Molitoris JK, Snider JW, Mossahebi S, Samanta S, Mohindra P et al. Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer. Journal of Thoracic Disease, Volume 10, Suppl 21, S2437-S2450, August 2018.
Regine WF, Â Snider J, et al. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, Volume 9, Issue 4, Pages 687-693, August 2018.
Vyfhuis MAL, Onyeuku N, Diwanji T, Mossahebi S, Amin NP, Mohindra P., et al. Advances in proton therapy in lung cancer. Therapeutic Advances in Respiratory Disease, Volume 12, July 2018.
Kwok Y, et al. An update from the Pediatric Proton Consortium Registry. Frontiers in Oncology, Volume 8, Article 165, May 2018.
Snider JW, et al. Long-Term Outcomes and Prognostic Factors After Pencil-Beam Scanning Proton Radiation Therapy for Spinal Chordomas: A Large, Single-Institution Cohort. International Journal of Radiation Oncology • Biology • Physics, Volume 101, Issue 1, Pages 226-233, May 2018.
Molitoris JK, Zhu M, Glass E, et al. Proton Beam therapy for malignant pleural mesothelioma. Translational Lung Cancer Research, Volume 7, Issue 2, Pages 189-198, April 2018.
Snider JW, et al. Long-Term Clinical Safety of High-Dose Proton Radiation Therapy Delivered With Pencil Beam Scanning Technique for Extracranial Chordomas and Chondrosarcomas in Adult Patients: Clinical Evidence of Spinal Cord Tolerance. International Journal of Radiation Oncology • Biology • Physics, Volume 100, Issue 1, Pages 218-225, January 2018.
Snider JW, et al. Long-Term Clinical Outcomes of Pencil Beam Scanning Proton Therapy for Benign and Non-benign Intracranial Meningiomas. International Journal of Radiation Oncology • Biology • Physics, Volume 99, Issue 5, Pages 1190-1198, December 2017.
Miller RC, et al. Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. International Journal of Radiation Oncology • Biology • Physics, Volume 99, Issue 5, Pages 1078-1082, December 2017.
Schneider C, Wyfhuis M, Diwanji T, Snider JW, Mossahebi S, Steacy K Dramatic Response of a Large Sacral Chordoma to Intensity Modulated Proton Beam Therapy. Cureus, Volume 9, Issue 9, e1670, September 2017.
Remick J, Regine W, Ng V, Wyfhuis M, Diwanji T, Shyu S, Snider JW Excellent Pathologic Response and Atypical Clinical Course of High-Grade Extremity Sarcoma to Neoadjuvant Pencil Beam Scanning Proton Therapy. Cureus, Volume 9, Issue 9, e1687, September 2017.
Miller RC, et al. Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice. International Journal of Radiation Oncology • Biology • Physics, Volume 98, Issue 4, Pages 840-842, July 2017.
Diwanji TP, Mohindra P, Vyfhuis M, Snider JW 3rd, Kalavagunta C, Mossahebi S, et al. Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Translational Lung Cancer Research, Volume 6, Issue 2, Pages 131-147, April 2017.
Mishra M, Bentzen S, Knight N, Regine WF, et al. Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology • Biology • Physics, Volume 97, Issue 2, Pages 228-235, November 2016.
Regine WF, et al. Comparison of Bolus Electron Conformal Therapy plans to Traditional Electron and Proton Therapy to Treat Melanoma in the Medial Canthus. Practical Radiation Oncology, Volume 6, Issue 2, Pages 105-109, March-April 2016.
Miller RC, et al. Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study. Physica Medica, Volume 32, Issue 2, Pages 331-342, February 2016.
Miller RC, et al. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiotherapy and Oncology, Volume 117, Issue 3, Pages 505-508, December 2015.
Molitoris JKÂ et al. Practical Method to Implement Arc Therapy Using Scanned Particle Beams. Medical Physics, Volume 42, Issue 6, Page 3480, June 2015.
Regine WF, et al. Is Proton Beam Therapy Better Than Standard Radiation Therapy? Clinical Advances in Hematology & Oncology, Volume 12, Issue 12, Pages 861-869, December 2014.
McAvoy, S.A, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. International Journal of Radiation Oncology • Biology • Physics, Volume 90, Issue 4, Pages 819-827, November 2014.
Regine WF, et al. Expanding the Horizons Of Proton Beam Therapy. Invited editorial. The Cancer Letter, Issue 31, August 2014.
McAvoy, S.A., et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiotherapy and Oncology, Volume 109, Issue 1, Pages 38-44, October 2013.
Miller RC, et al. Controversies in clinical trials in proton radiotherapy: the present and the future. Seminars in Radiation Oncology, Volume 23, Issue 2, Pages 127-133, April 2013.
Miller RC, et al. The clinical case for proton beam therapy. Radiation Oncology, Volume 7:164, October 22, 2012.
Regine WF, Prado K, et al. Protons Offer Reduced Normal Tissue Exposure for Patients Receiving Postoperative Radiotherapy (RT) for Resected Pancreatic Head Cancer. International Journal of Radiation Oncology • Biology • Physics, Volume 83, Issue 1, Pages 158-163, May 2012.
Miller RC, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. International Journal of Radiation Oncology • Biology • Physics, Volume 75, Issue 3, Pages 950-958, November 2009.
